Gepants for the treatment of migraine.
Andrea NegroPaolo MartellettiPublished in: Expert opinion on investigational drugs (2019)
Available data suggest that second generation of gepants has clinical efficacy similar to triptans and lasmiditan (5-HT1F receptor agonist) and has improved tolerability. Future studies will assess their safety, especially in specific populations such as patients with cardiovascular disease and pregnant women.
Keyphrases
- pregnant women
- cardiovascular disease
- electronic health record
- big data
- open label
- current status
- clinical trial
- randomized controlled trial
- metabolic syndrome
- machine learning
- case control
- artificial intelligence
- deep learning
- combination therapy
- pregnancy outcomes
- replacement therapy
- data analysis
- genetic diversity
- study protocol
- placebo controlled